CD14 and COVID-19: When the different monocyte subsets were determined (Figure 3A-C) a significant increase in intermediate monocytes (iMon; CD56-CD14+CD16+) of COVID19 patients in comparison with HDs and NON-COV-RTI and a significant decrease in non-classical monocytes (ncMon; CD56-CD14-CD16High) with respect to HDs were found.